Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01625338




Registration number
NCT01625338
Ethics application status
Date submitted
7/06/2012
Date registered
21/06/2012
Date last updated
9/11/2015

Titles & IDs
Public title
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Scientific title
An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Secondary ID [1] 0 0
2012-000571-16
Secondary ID [2] 0 0
GS-US-334-0109
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis C 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SOF
Treatment: Drugs - RBV
Treatment: Drugs - Peg-IFN

Experimental: SOF+RBV 12 Weeks - SOF+RBV for 12 weeks

Experimental: SOF+RBV 24 Weeks - SOF+RBV for 24 weeks

Experimental: SOF+RBV+Peg-IFN 12 Weeks - SOF+RBV+Peg-IFN for 12 weeks


Treatment: Drugs: SOF
SOF 400 mg tablet administered orally once daily

Treatment: Drugs: RBV
RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and = 75 kg = 1200 mg)

Treatment: Drugs: Peg-IFN
Peg-IFN 180 µg administered once weekly by subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Timepoint [1] 0 0
Posttreatment Week 12
Primary outcome [2] 0 0
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Timepoint [2] 0 0
Up to 24 weeks
Secondary outcome [1] 0 0
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
Timepoint [1] 0 0
Posttreatment Weeks 4 and 24
Secondary outcome [2] 0 0
Percentage of Participants With On-treatment Virologic Failure
Timepoint [2] 0 0
Up to 24 weeks
Secondary outcome [3] 0 0
Percentage of Participants With Viral Relapse
Timepoint [3] 0 0
Up to Posttreatment Week 24

Eligibility
Key inclusion criteria
* Infection with HCV
* Must have participated in a prior Gilead HCV study
* Use of highly effective contraception methods if female of childbearing potential or sexually active male
* Eligible patients include those in the following

* received placebo or Peg-IFN+RBV in a control arm
* previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing:

* Sofosbuvir+RBV
* Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant or nursing female or male with pregnant female partner
* Current or prior history of clinical hepatic decompensation
* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
* Chronic use of systemically administered immunosuppressive agents
* Active drug abuse
* Use of any prohibited concomitant medications

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
534
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Gallipoli Medical Research Foundation - Greenslopes
Recruitment hospital [4] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [6] 0 0
Monash Medical Centre - Melbourne
Recruitment hospital [7] 0 0
B2 Clinic - Fremantle
Recruitment hospital [8] 0 0
Canberra Hospital - Australian Capital Territory
Recruitment hospital [9] 0 0
St. Vincent's Hospital - Fitzroy
Recruitment hospital [10] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment hospital [11] 0 0
St George Hospital - Kogarah
Recruitment hospital [12] 0 0
Royal Prince Alfred Hospital, Camperdown - NSW
Recruitment hospital [13] 0 0
Royal Perth Hospital - Perth Western Australia
Recruitment hospital [14] 0 0
Princess Alexandra Hospital - State of Queensland
Recruitment hospital [15] 0 0
Box Hill Hospital - Victoria
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4120 - Greenslopes
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
3168 - Melbourne
Recruitment postcode(s) [7] 0 0
6160 - Fremantle
Recruitment postcode(s) [8] 0 0
2605 - Australian Capital Territory
Recruitment postcode(s) [9] 0 0
3065 - Fitzroy
Recruitment postcode(s) [10] 0 0
QLD 4029 - Herston
Recruitment postcode(s) [11] 0 0
2217 - Kogarah
Recruitment postcode(s) [12] 0 0
2050 - NSW
Recruitment postcode(s) [13] 0 0
6000 - Perth Western Australia
Recruitment postcode(s) [14] 0 0
4102 - State of Queensland
Recruitment postcode(s) [15] 0 0
3128 - Victoria
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Rhode Island
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
Austria
State/province [22] 0 0
Graz
Country [23] 0 0
Austria
State/province [23] 0 0
Vienna
Country [24] 0 0
Austria
State/province [24] 0 0
Wien
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
Canada
State/province [27] 0 0
Manitoba
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Canada
State/province [29] 0 0
Quebec
Country [30] 0 0
Canada
State/province [30] 0 0
Vancouver
Country [31] 0 0
Czech Republic
State/province [31] 0 0
Praha 4
Country [32] 0 0
Estonia
State/province [32] 0 0
Tallinn
Country [33] 0 0
Estonia
State/province [33] 0 0
Tartu
Country [34] 0 0
France
State/province [34] 0 0
Clermont-Ferrand
Country [35] 0 0
France
State/province [35] 0 0
Clichy
Country [36] 0 0
France
State/province [36] 0 0
Creteil Cedex
Country [37] 0 0
France
State/province [37] 0 0
Lille
Country [38] 0 0
France
State/province [38] 0 0
Marseille
Country [39] 0 0
France
State/province [39] 0 0
Montpellier
Country [40] 0 0
France
State/province [40] 0 0
Nice
Country [41] 0 0
France
State/province [41] 0 0
Paris Cedex 12
Country [42] 0 0
France
State/province [42] 0 0
Paris Cedex 13
Country [43] 0 0
France
State/province [43] 0 0
Pessac Cedex
Country [44] 0 0
France
State/province [44] 0 0
Rennes Cedex 9
Country [45] 0 0
France
State/province [45] 0 0
Strasbourg
Country [46] 0 0
France
State/province [46] 0 0
Vandoeuvre-les-Nancy
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Bonn
Country [49] 0 0
Germany
State/province [49] 0 0
Düsseldorf
Country [50] 0 0
Germany
State/province [50] 0 0
Frankfurt am Main
Country [51] 0 0
Germany
State/province [51] 0 0
Freiburg im Breisgau
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Hannover
Country [54] 0 0
Germany
State/province [54] 0 0
Heidelberg
Country [55] 0 0
Germany
State/province [55] 0 0
Herne
Country [56] 0 0
Germany
State/province [56] 0 0
Kiel
Country [57] 0 0
Germany
State/province [57] 0 0
Leipzig
Country [58] 0 0
Germany
State/province [58] 0 0
Muenster
Country [59] 0 0
Germany
State/province [59] 0 0
Munich
Country [60] 0 0
Germany
State/province [60] 0 0
Wurzburg
Country [61] 0 0
Italy
State/province [61] 0 0
Foggia
Country [62] 0 0
Italy
State/province [62] 0 0
Florence
Country [63] 0 0
Italy
State/province [63] 0 0
Genoa
Country [64] 0 0
Italy
State/province [64] 0 0
Milano
Country [65] 0 0
Italy
State/province [65] 0 0
Milan
Country [66] 0 0
Italy
State/province [66] 0 0
Padova
Country [67] 0 0
Italy
State/province [67] 0 0
Parma
Country [68] 0 0
Italy
State/province [68] 0 0
Roma
Country [69] 0 0
Italy
State/province [69] 0 0
Rome
Country [70] 0 0
Italy
State/province [70] 0 0
Turin
Country [71] 0 0
Netherlands
State/province [71] 0 0
Amsterdam
Country [72] 0 0
Netherlands
State/province [72] 0 0
Nijmegen
Country [73] 0 0
Netherlands
State/province [73] 0 0
Rotterdam
Country [74] 0 0
New Zealand
State/province [74] 0 0
Auckland
Country [75] 0 0
New Zealand
State/province [75] 0 0
BOP
Country [76] 0 0
New Zealand
State/province [76] 0 0
WGN
Country [77] 0 0
New Zealand
State/province [77] 0 0
Christchurch
Country [78] 0 0
New Zealand
State/province [78] 0 0
Dunedin
Country [79] 0 0
New Zealand
State/province [79] 0 0
Hamilton
Country [80] 0 0
Poland
State/province [80] 0 0
Bialystok
Country [81] 0 0
Poland
State/province [81] 0 0
Chorzow
Country [82] 0 0
Poland
State/province [82] 0 0
Lodz
Country [83] 0 0
Poland
State/province [83] 0 0
Myslowice
Country [84] 0 0
Poland
State/province [84] 0 0
Warsaw
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
San Juan
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
Madrid
Country [88] 0 0
Spain
State/province [88] 0 0
Majadahonda
Country [89] 0 0
Spain
State/province [89] 0 0
Malaga
Country [90] 0 0
Spain
State/province [90] 0 0
Sevilla
Country [91] 0 0
Spain
State/province [91] 0 0
Valencia
Country [92] 0 0
Sweden
State/province [92] 0 0
Göteborg
Country [93] 0 0
Sweden
State/province [93] 0 0
Malmo
Country [94] 0 0
Sweden
State/province [94] 0 0
Stockholm
Country [95] 0 0
United Kingdom
State/province [95] 0 0
London
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Birmingham
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Hampshire
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Manchester
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).
Trial website
https://clinicaltrials.gov/study/NCT01625338
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bittoo Kanwar, MD
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01625338